Skip to main content
HCPCS C9312 · Level II · Part B drug

C9312: trabectedin (Evdi), HCPCS Level II drug code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: OPPS Addendum B: October 2026 (effective October 1, 2026); OPPS NDC-HCPCS crosswalk: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for C9312

Billing unit
0.01 MG
Inj trabecte apotex, 0.01 mg
OPPS payment rate
$46.71
no ASP limit; SI G, October 2026
Practitioner MUE
none published
CMS publishes no MUE for this code
OPPS status
SI G
APC 0959
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS C9312 is the Level II code for Injection, trabectedin (apotex), not therapeutically equivalent to j9362, 0.01 mg, billed per 0.01 MG. CMS publishes no ASP payment limit for it; hospital outpatient departments are paid separately under OPPS (status indicator G, $46.71 per billing unit in October 2026). With a 1 mg billing unit, a single administration can be hundreds of units; the unit count on the claim must equal the milligrams given, and rounding rules for partial units follow the contractor's guidance. Other HCPCS codes whose descriptor names trabectedin: J9362 (Yondelis from Janssen Products, LP). The OPPS crosswalk maps 1 NDC to it, sold as Evdi by Apotex Corp. No current Billing and Coding Article lists C9312, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare payment: OPPS rate (no ASP limit)

C9312 does not appear in the October 2026 Part B ASP payment limit file. CMS pays it separately to hospital outpatient departments under OPPS with status indicator G in APC 0959, at a national unadjusted rate of $46.71 per 0.01 MG. Status G is drug pass-through payment, which lasts a limited number of years. In a physician office the Medicare contractor prices the drug, often from invoice; commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 OPPS crosswalk maps 1 NDC from 1 labeler to C9312. Report the NDC in the claim's drug segment and bill the number of C9312 units that equals the quantity administered divided by 0.01 MG; the last column gives units per full package.

NDCs that crosswalk to C9312
NDCDrug nameLabelerPackage sizeBilling units / package
60505-6423-00EvdiApotex Corp20 × 1100

Medically Unlikely Edits (MUE)

CMS does not publish an MUE for C9312 in the 2026 Q4 tables. Some MUE values are confidential and applied without publication, so unit limits can still deny; document the dose and the units calculation on every claim.

MUE for C9312 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists C9312 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check C9312 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

C9312 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists C9312 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, C9312 carries status indicator G and is assigned to APC 0959, with a published national unadjusted payment of $46.71. Status G marks pass-through drug payment, which is time-limited.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), C9312 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $46.71 per 0.01 MG, paid only when the drug is furnished integral to a covered surgical procedure.

Common denials for C9312 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for C9312

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS C9312

What does HCPCS code C9312 describe?

C9312 is defined by CMS as "Injection, trabectedin (apotex), not therapeutically equivalent to j9362, 0.01 mg". Each billing unit represents 0.01 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is C9312 a CPT code?

No. C9312 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as trabectedin (Evdi); CPT codes are five-character codes maintained by the AMA. On a Part B claim C9312 reports the drug itself in 0.01 mg units, and the administration is billed on its own line.

What does Medicare pay for C9312 in a hospital outpatient department?

C9312 has no Part B ASP limit; the October 2026 OPPS Addendum B pays it separately under status G, APC 0959, at $46.71 per 0.01 MG, and ASC Addendum BB gives it payment indicator K2 at $46.71.

Which NDCs map to C9312?

The October 2026 OPPS crosswalk lists 1 NDC from 1 labeler: Evdi (Apotex Corp). For example NDC 60505-6423-00 (package size 20) equals 100 billing units of C9312.

Does C9312 have NCCI bundling edits?

No active practitioner PTP pairs list C9312 as a column-1 or column-2 code in the v323r0 release.

C9312 vs J9362: what is the difference?

Both are HCPCS Level II codes whose descriptor names trabectedin. What sets J9362 apart: Yondelis from Janssen Products, LP. C9312 is billed per 0.01 mg, OPPS rate $46.71; J9362 is billed per 0.01 mg, limit $41.844. Report the code whose descriptor matches the product and setting in the record.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.